Definium Therapeutics Inc. (NASDAQ:DFTX) shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder—with the trial meeting its primary and all key secondary efficacy endpoints.
- Definium stock is challenging resistance. Why is DFTX stock breaking out?
The Results
The Emerge study evaluated a single dose of DT120 ODT 100 µg—a lysergide-based treatment—in a randomized, double-blind, placebo-controlled Phase 3 trial. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo at Week 6. The placebo-adjusted change from baseline in MADRS total score was 8.1 points at Week 6 (p<0.0001), the primary endpoint, and 7.3 points at Week 12, a secondary endpoint (p<0.0001).
Notably, the effect was also rapid, a placebo-adjusted reduction of 14.2 points was observed at just Week 1 (p<0.0001), suggesting DT120 could offer faster relief than existing antidepressants, which typically take weeks to show meaningful benefit.
Safety Profile
DT120 ODT was generally well tolerated. Ninety-nine percent of treatment-emergent adverse events were mild to moderate in severity, transient and predominantly occurring on the day of dosing. No serious adverse events were reported, no suicidality signal was identified and discontinuation rates were low and comparable between treatment and placebo groups.
Why It Matters
Major depressive disorder affects hundreds of millions of people globally, and existing treatments leave many patients with partial responses, frequent medication changes, and long-term side effects. A single-dose treatment delivering rapid, robust, and durable relief would represent a fundamentally new approach to MDD management. Definium said the results strengthen its confidence in DT120 as a potential best-in-class treatment and bring the company one step closer to FDA submission.
“The Emerge topline results represent unprecedented and highly differentiated efficacy,” said Rob Barrow, CEO of Definium Therapeutics. “These findings could support a fundamentally new approach to treating MDD for patients and providers who continue to face the limitations of existing treatment options.”
Definium Shares Surge
DFTX Price Action: At the time of publication, Definium shares are trading 63.52% higher at $40.03, according to data from Benzinga Pro.
Image via Shutterstock
Login to comment